Augmenix Inc. said today that long-term outcomes data from the company’s phase III clinical trial evaluating its hydrogel spacer, SpaceOAR, was published in the International Journal of Radiation Oncology Biology and Physics. The spacer is designed to separate the rectum and prostate during prostate cancer radiotherapy, according to the Waltham, Mass.-based company.
The newly published data was collected 3 years after patients were treated with the spacer in the randomized trial. The SpaceOAR is injected as a liquid and then solidifies as a soft hydrogel that pushes the rectum out of the high-dose radiation field during radiation therapy. Following treatment, the hydrogel is absorbed by the body.